SEARCH LEGDISORDERS.ORG
BOLD Steering Committee

Michael J. Thorpy, MD

Chairperson

Emile R. Mohler III, MD

Chairperson

John S. Sundy, MD, PhD

Chairperson
Poll
Which of the following leg disorders do you encounter most frequently in your practice?





Educational Links
You need to upgrade your Flash Player
You need to upgrade your Flash Player to view this content.
Dynamic Slide Library Index



Fibromylagia

Fibromylagia
Gabapentin Versus Placebo for Treatment of Fibromyalgia
Gabapentin vs Placebo at Week 12 for Treatment of Fibromyalgia
Efficacy of Gabapentin for Treatment of Fibromyalgia
Efficacy of Group Exercise, Education, Combination Self-Management Treatments in Women with Fibromyalgia
Benefits of Exercise and Self-Management Education in Women with FM
Fibromyalgia: Prevalence
Fibromyalgia: Pathogenesis
Fibromyalgia: Management
 


Gout

Gout
Gout: Epidemiology
Gout: Clinical Phases
Gout: Diagnostic Gold Standard
Acute Gouty Arthritis
Prevalence of Gout Increases With Age
Intercritical Gout
 


Nocturnal Leg Cramps

Nocturnal Leg Cramps
Nocturnal Leg Cramps: Diagnostic Criteria
Nocturnal Leg Cramps: Pathophysiology
Possible Causes of Nocturnal Leg Cramps
Nocturnal Leg Cramps: Treatment Strategies
Efficacy of Quinine Sulfate* for Nocturnal Leg Cramps
Quinine Sulfate for Nocturnal Leg Cramps: Associated Risks
Nocturnal Leg Cramps (NLC): Epidemiology
Orphenadrine Citrate* or Verapamil* for NLC
 


Osteoarthritis

Osteoarthritis
Osteoarthritis
Clinical Features of Osteoarthritis
Presence of OA in Joints Affected by Gout
Association Between Site of Acute Gout Attacks and Presence of OA
OA: Epidemiology
OA: Physical Examination
Differential Diagnosis: RA or OA?
 


Periodic Limb Movement Disorder (PLMD)

Periodic Limb Movement Disorder
Periodic Limb Movement Disorder (PLMD)
Periodic Limb Movement Disorder (PLMD): Pathophysiology
PLMD: Risk Factors and Secondary Causes
Treatment Strategies for PLMD
Pharmacologic Agents for Treating RLS and PLMD
Periodic Limb Movements in Sleep (PLMS)
Identification of PLMs
 


Peripheral Arterial Disease (PAD)

Peripheral Arterial Disease (PAD)
Peripheral Arterial Disease (PAD)
Prevalence of Peripheral Arterial Disease (PAD)
PAD: Location of Lesion
PAD: Leg Symptoms
Risk Factors for Peripheral Arterial Disease
PAD and Cardiovascular Disease (CVD)
Treatment Goals for Peripheral Arterial Disease
PAD: Pharmacologic Treatments
PAD: Nonpharmacologic Treatments
Survey: Public Awareness of PAD
Prevalence of Leg Symptoms Among PAD Awareness Survey Participants
Survey Results Show Gaps in Knowledge About PAD
WAVE: Anticoagulant and Antiplatelet Combination Therapy for PAD
WAVE: Incidence of Co-Primary Endpoints
WAVE Study: Results
Two Major Goals in Treating Patients With PAD
Relative Efficacy to Improve Walking Distance in Claudication
Low ABI Predicts All‑Cause Mortality
 


Peripheral Neuropathies

Peripheral Neuropathies
Symptoms of Diabetic Peripheral Neuropathy
Treatment Strategies for Diabetic Peripheral Neuropathy
Prescription Medication Use By Patients With DPN
Peripheral Neuropathy
FDA-Approved Treatments for Neuropathic Pain Syndromes
Nonpharmacologic Treatments for Peripheral Neuropathy
Sensory Abnormalities in Neuropathic Pain Syndromes
Safety and Efficacy in Neuropathic Pain

Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Symptoms of Diabetic Peripheral Neuropathy
Treatment Strategies for Diabetic Peripheral Neuropathy
Prescription Medication Use By Patients With DPN
Differential Diagnosis of DPN
 


Restless Legs Syndrome (RLS)

Restless Legs Syndrome (RLS)
Pharmacologic Agents for Treating RLS and PLMD
Core Symptoms of Restless Legs Syndrome (RLS)
Restless Legs Syndrome (RLS): Epidemiology
Restless Legs Syndrome (RLS): Pathophysiology
Agents That May Precipitate RLS
Treatment Strategies for RLS
Nonpharmacologic Treatments for Restless Legs Syndrome (RLS)
Effect-RLS: Efficacy of Pramipexole
Effect-RLS Study: Change in IRLS Score
Effect-RLS: Safety and Efficacy of Pramipexole
Genome-Wide Association Study (GWAS) of RLS
Efficacy and Safety of Pramipexole in RLS: The PRELUDE Study
Mean IRLS Total Scores: Ropinirole vs Placebo
 


Rheumatoid Arthritis


Rheumatoid Arthritis
Abatacept for the Treatment of Rheumatoid Arthritis
AIM: Abatacept Improves Symptoms of RA and Physical Functioning
TEMPO: Combination Etanercept and Methotrexate for RA
TEMPO: Results
RA: Epidemiology and Risk Factors
Differential Diagnosis: RA or OA?
Clinical Features of RA
Pathophysiology of RA
RA Management: Partnership Approach
 


Varicose Veins

Varicose Veins
Varicose Veins
Treatment Options for Varicose Veins
 


Venous Thromboembolism (VTE)

Deep Vein Thrombosis (DVT)
Deep Vein Thrombosis (DVT)
Diagnosis of Deep Vein Thrombosis
Deep Vein Thrombosis in Leg Veins
DVT: Exogenous Risk Factors
Treatment Strategies for DVT
DVT and PE Increase With Age
Venous Thromboembolism (VTE)
Venous Thromboembolism (VTE): Epidemiology
VTE Incidence Rate: Sex and Age Group
Guidelines for Management of Venous Thromboembolism (1 of 2)
Guidelines for Management of Venous Thromboembolism (2 of 2)

Venous Thromboembolism (VTE)
DVT: Exogenous Risk Factors
Venous Thromboembolism (VTE)
Venous Thromboembolism (VTE): Epidemiology
VTE Incidence Rate: Sex and Age Group
Guidelines for Management of Venous Thromboembolism (1 of 2)
Guidelines for Management of Venous Thromboembolism (2 of 2)
EXPERT: Safety and Efficacy of Fondaparinux for Prevention of VTE
EXPERT Study: Results

Pulmonary Embolism (PE)
DVT: Exogenous Risk Factors
Venous Thromboembolism (VTE)
Venous Thromboembolism (VTE): Epidemiology
Guidelines for Management of Venous Thromboembolism (1 of 2)
Guidelines for Management of Venous Thromboembolism (2 of 2)